Search results
Macrogenics Stock Drops 77% After Study Deaths
The Wall Street Journal· 7 hours agoMacroGenics shares plunged 77.4% on Friday, erasing $773.2 million in market value, after the biotech reported late Thursday that five patients died in a...
Catalyst's New CEO Has Big Ideas For The Small Biotech
Investor's Business Daily· 14 hours agoIn an interview with Investor's Business Daily, Daly recalled how...over the past nine years from...
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug...
Digital Journal· 16 hours ago(the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter ...
Sean ‘Diddy’ Combs asks judge to dismiss ‘false’ claim that he, others raped 17-year-old girl
FOX 12 Oregon· 2 hours ago“Mr. Combs and his companies categorically deny Plaintiff’s decades-old tale against them, which has...
Pot-Focused Finance Company Reports Higher Investment Income, Projects 'Increase In Cannabis Capital...
Benzinga· 14 hours agoSilver Spike Investment Corp. SSIC, a specialty finance company that has elected to be regulated as...
Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows By Reuters
Investing.com· 10 hours agoThe data also showed that 6% of those polled said they were currently using a GLP-1 drug, such as...
IQ-AI subsidiary wins FDA designation for lead drug candidate
Proactive Investors· 12 hours agoImaging Biometrics, a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has announced that the US...
Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows
Reuters· 10 hours agoAbout one in eight adults have taken a drug belonging to the GLP-1 class of medications for weight...
Maze lands new partner for Pompe drug, after Sanofi pact came apart
BioPharma Dive via Yahoo Finance· 18 hours agoDive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi,...
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Reuters via Yahoo Finance· 19 hours agoHYDERABAD/BENGALURU (Reuters) -Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said ...